Coya Therapeutics (COYA) Current Deferred Revenue (2023 - 2026)

Coya Therapeutics (COYA) has 4 years of Current Deferred Revenue data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 47.68% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 47.68% YoY), and the FY2025 full-year result was $1.2 million, up 41.21% from the prior year.
• Current Deferred Revenue improved to $1.2 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q1 2026 to a low of $573089.0 in Q3 2024.
• A 4-year average of $890288.0 and a median of $882499.0 in 2024 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 59.96% in 2025, while the deepest fall reached 22.15% in 2025.
• Tracing COYA's Current Deferred Revenue over 4 years: stood at $923109.0 in 2023, then declined by 8.11% to $848286.0 in 2024, then soared by 41.21% to $1.2 million in 2025, then gained by 3.74% to $1.2 million in 2026.
• Business Quant data shows COYA's Current Deferred Revenue at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $916712.0 in Q3 2025.